WHO takes up the baton on dementia. Lancet Neurol. 2015;14:455.
Herrmann, N, Harimoto, T, Balshaw, R, Lanctot, KL. Risk factors for progression of Alzheimer Disease in a Canadian population: the Canadian Outcomes Study in Dementia (COSID). Can J Psychiatry. 2015;60:189-199.
Sperling, RA, Aisen, PS, Beckett, LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280-292.
Gomersall, T, Astell, A, Nygard, L, Sixsmith, A, Mihailidis, A, Hwang, A. Living with ambiguity: a metasynthesis of qualitative research on mild cognitive impairment. Gerontologist. 2015;55:892-912.
Strong, MJ, Grace, GM, Freedman, M, et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10:131-146.
Woolley, SC, Strong, MJ. Frontotemporal dysfunction and dementia in amyotrophic lateral sclerosis. Neurol Clin. 2015;33:787-805.
Dorsey, ER, Constantinescu, R, Thompson, JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384-386.
Aarsland, D, Zaccai, J, Brayne, C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord. 2005;20:1255-1263.
Hely, MA, Reid, WG, Adena, MA, Halliday, GM, Morris, JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23:837-844.
Kertesz, A. Frontotemporal dementia/Pick’s disease. Arch Neurol. 2004;61:969-971.
Saposnik, G, Cote, R, Rochon, PA, et al. Care and outcomes in patients with ischemic stroke with and without preexisting dementia. Neurology. 2011;77:1664-1673.
Saposnik, G, Black, SE, Hakim, A, Fang, J, Tu, JV, Kapral, MK. Age disparities in stroke quality of care and delivery of health services. Stroke. 2009;40:3328-3335.
Pendlebury, ST, Mariz, J, Bull, L, Mehta, Z, Rothwell, PM. MoCA, ACE-R, and MMSE versus the National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards Neuropsychological Battery after TIA and stroke. Stroke. 2012;43:464-469.
Hachinski, V, Iadecola, C, Petersen, RC, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006;37:2220-2241.
Montero-Odasso, M, Casas, A, Hansen, KT, et al. Quantitative gait analysis under dual-task in older people with mild cognitive impairment: a reliability study. J Neuroeng Rehabil. 2009;6:35.
Montero-Odasso, M, Muir, SW, Speechley, M. Dual-task complexity affects gait in people with mild cognitive impairment: the interplay between gait variability, dual tasking, and risk of falls. Arch Phys Med Rehabil. 2012;93:293-299.
Ghani, M, Lang, AE, Zinman, L, et al. Mutation analysis of patients with neurodegenerative disorders using NeuroX array. Neurobiol Aging. 2015;36(545):e549-514.
Ballard, CG, Morris, CM, Rao, H, et al. APOE epsilon4 and cognitive decline in older stroke patients with early cognitive impairment. Neurology. 2004;63:1399-1402.
Tsuang, D, Leverenz, JB, Lopez, OL, et al. APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurol. 2013;70:223-228.
Xi, Z, Zinman, L, Grinberg, Y, et al. Investigation of c9orf72 in 4 neurodegenerative disorders. Arch Neurol. 2012;69:1583-1590.
Friedman, L, Stern, H, Brown, GG, Mathalon, DH, Turner, J, Glover, GH, et al. Test-retest and between-site reliability in a multicenter fMRI study. Hum Brain Mapp. 2008;29:958-972.
Nestor, SM, Gibson, E, Gao, FQ, Kiss, A, Black, SE. A direct morphometric comparison of five labeling protocols for multi-atlas driven automatic segmentation of the hippocampus in Alzheimer’s disease. Neuroimage. 2013;66:50-70.
Nestor, SM, Rupsingh, R, Borrie, M, et al. Ventricular enlargement as a possible measure of Alzheimer’s disease progression validated using the Alzheimer’s disease neuroimaging initiative database. Brain. 2008;131:2443-2454.
Dade, LA, Gao, FQ, Kovacevic, N, et al. Semiautomatic brain region extraction: a method of parcellating brain regions from structural magnetic resonance images. Neuroimage. 2004;22:1492-1502.
Ramirez, J, Gibson, E, Quddus, A, et al. Lesion Explorer: a comprehensive segmentation and parcellation package to obtain regional volumetrics for subcortical hyperintensities and intracranial tissue. Neuroimage. 2011;54:963-973.
Wahlund, LO, Julin, P, Lindqvist, J, Scheltens, P. Visual assessment of medical temporal lobe atrophy in demented and healthy control subjects: correlation with volumetry. Psychiatry Res. 1999;90:193-199.
Scheltens, P, Leys, D, Barkhof, F, et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55:967-972.
Fazekas, F, Chawluk, JB, Alavi, A, Hurtig, HI, Zimmerman, RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol. 1987;149:351-356.
Scheltens, P, Barkhof, F, Leys, D, et al. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci. 1993;114:7-12.
Cordonnier, C, Potter, GM, Jackson, CA, et al. improving interrater agreement about brain microbleeds: development of the Brain Observer MicroBleed Scale (BOMBS). Stroke. 2009;40:94-99.
Holmes, C, Boche, D, Wilkinson, D, et al. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216-223.
Iadecola, C, Anrather, J. Stroke research at a crossroad: asking the brain for directions. Nat Neurosci. 2011;14:1363-1368.
Lang, AE. Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. Nat Med. 2010;16:1223-1226.
Farhan, SM, Dilliott, AA, Ghani, M, et al. The ONDRISeq panel: custom designed next generation sequencing of genes related to neurodegeneration. Genom Med. 2016; Article number 16032;doi:10.1038/npjgenmed.2016.32.